Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

C16TR

Small molecule · developed by Insmed

Phase 1 Most advanced trial (none active)
INSM Developer
1 Registered trials

What is C16TR?

C16TR (hexadecyl-treprostinil) is an inhaled formulation administered with a Philips Micro device inhaler.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Hexadecyl-treprostinil
Drug type
Small molecule
Developer
Insmed Incorporated (INSM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06193031 Phase 1 Healthy Volunteers Completed INSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Insmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.

Follow INSM, the company behind C16TR

See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INSM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.